STOCKHOLM–(BUSINESS WIRE)–Regulatory News: NeuroVive Pharmaceutical AB (publ)(STO:NVP), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using […]
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: As previously informed, Karo Bio (STO:KARO) has signed an agreement to acquire 100 % of the shares in Tanomed AB against payment in shares in Karo Bio […]
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: A Chinese study of infants with colic shows that babies given Lactobacillus reuteri Protectis cry significantly less compared to babies given placebo. The newly published study is […]
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Moberg Pharma AB (STO:MOB) has acquired Balmex®, a well-established Over-The-Counter brand in the U.S. from Chattem, Inc, the U.S. Consumer Healthcare Division of Sanofi. Net sales of […]
SOLNA, Sweden–(BUSINESS WIRE)–Regulatory News: Aerocrine AB (STO:AEROB) responds to recent speculation in the market. Aerocrine has noted recent speculation in the markets. The Board of Aerocrine confirms that it is […]
LONDON–(BUSINESS WIRE)–The Cell Therapy Catapult and Asymptote, a leading specialist in cryopreservation, based in Cambridge, UK, are combining forces to advance the development of a novel point-of-care Thawing System for […]
More information about the highly anticipated new cholesterol lowering drugs from Amgen and Sanofi/Regeneron emerged today. A new new analysis of available data from early trials with PCSK9 inhibitors adds to the growing evidence […]
The shift in the healthcare landscape from volume to value has created new challenges, new opportunities, and a new dynamic among healthcare stakeholders. Despite the varying needs this environment has produced, there is one unifying goal: improved patient outcomes. Executives say this goal is not a new area of focus for MicroMass Communications.
Executives say at an agency-wide meeting in March 2014, Natrel founder David Nakamura shared his vision for doubling the 15-year-old agency’s size by 2017. The plan focused on expanding Natrel’s digital, strategic, scientific, and patient marketing expertise through best-in-class hiring, and on repositioning the agency to reflect its commitment to a unique, internally developed approach to brand differentiation. Nakamura assumed it would take about one year to shore up departments and another two years to bring in new accounts. According to agency leaders, he had everything right but the numbers.
In 2014, The Navicor Group, the only oncology-focused agency, celebrated its 10-year anniversary with 30 percent top-line growth and the expansion of an independently operating office in Center City, Philadelphia.
The year’s accomplishments
Heading into 2015, Navicor is poised for significant growth – with new-business win rates exceeding 70 percent in both 2013 and 2014 and a creative product that is resonating in the market, executive say. “Our collaborative approach, depth of perspective in oncology, and fresh thinking have resulted in more than 70 awards over the last two years for our AOR clients,” says Rich D’Ginto, senior VP, executive creative director.
